EIF2AK3 and B-cell chronic lymphocytic leukemia: Given that fludarabine-resistant model 2 cells expressed higher levels of PERK, the reduced eIF2 signalling observed in these cells, as well as in pre-treatment samples from CLL patients who responded sub-optimally to FCR, may seem paradoxical.